The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia

Status:
Completed

Trial end date:
2017-01-24

Target enrollment:

Participant gender:

The purpose of this study is to evaluate the efficacy and safety of volanesorsen given for 26 weeks in patients with Hypertriglyceridemia

Phase 3

Ionis Pharmaceuticals, Inc.

Akcea Therapeutics